Every Form 4 that Beam Therapeutics Inc. (BEAM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BEAM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEAM filings page.
At Beam Therapeutics Inc., SVP, Finance and Treasurer Bethany J. Cavanagh sold 187 shares of common stock on October 1, 2026, at $24.41 per share. The shares were automatically sold in a non-discretionary transaction to cover tax withholding obligations upon vesting of restricted stock units granted to her on September 30, 2024. The sale was made under a Rule 10b5-1 trading plan adopted on August 9, 2024; she held 50,984 shares directly after the sale.
Beam Therapeutics Inc. President Giuseppe Ciaramella contributed 123,407 shares of common stock to the Giuseppe Ciaramella Irrevocable Trust - 2026 on September 24, 2026. After the gift, he reported 130,504 shares held directly; 123,407 shares were reported indirectly through the trust. His spouse is the trustee, and the beneficiaries are his spouse and children. Ciaramella disclaimed beneficial ownership of the trust's securities. No Rule 10b5-1 plan is reported.
Beam Therapeutics Inc. reports that Chief Medical Officer Simon Amy sold 16,667 shares of common stock on July 27, 2026 at a weighted average price of $25.7417 per share, in multiple trades between $25.32 and $26.05, under a Rule 10b5-1 trading plan adopted on March 27, 2026. Following these sales, the reporting person directly owns 85,696 shares of Beam Therapeutics common stock.
Beam Therapeutics Inc. Chief Medical Officer Amy Simon reported an open-market sale of 373 shares of common stock at $34.73 per share. According to the disclosure, these shares were automatically sold in a non-discretionary transaction to cover tax withholding obligations upon vesting of restricted stock units granted under the 2019 Equity Incentive Plan. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Simon directly holds 102,363 shares of Beam Therapeutics common stock.
Beam Therapeutics Inc. CEO John M. Evans reported a series of option exercises and related share sales in Beam Therapeutics common stock. He exercised options covering 50,000 shares at strike prices of $1.03 and $0.67 per share, then sold 50,000 shares in open-market transactions at weighted average prices in the mid-$30s.
The filing shows these trades were executed pursuant to a Rule 10b5-1 trading plan. Following the transactions, Evans continues to hold over 1.0 million shares of Beam Therapeutics common stock directly, and 103,000 shares indirectly through the John M. Evans, III 2018 Irrevocable Trust.
FMR LLC, a ten percent owner of Beam Therapeutics Inc., reported indirect open-market sales of Beam common stock through F-Prime Capital Partners Healthcare Fund V LP.
The entity sold 33,372 shares on June 25, 2026 at a weighted average price of $35.12 per share, and 251,488 shares on June 26, 2026 at a weighted average price of $35.26 per share, for total reported sales of 284,860 shares. After these transactions, one reported indirect holding shows 854,583 shares remaining for the F-Prime Capital Partners Healthcare Fund V LP position. Additional indirect holdings include 841,231 shares held by persons and entities whose shares are subject to reporting by FMR LLC and 14 shares held by FMR Capital, Inc.
Beam Therapeutics Inc. president Giuseppe Ciaramella reported exercising stock options to acquire a total of 35,505 shares of common stock on June 17, 2026. These transactions were coded “M,” indicating exercises or conversions of derivative securities rather than open‑market purchases or sales.
The options exercised carried strike prices of $1.03 and $0.67 per share. The underlying options had vesting schedules beginning February 26, 2018, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments, reflecting long-term equity compensation.
Beam Therapeutics director Christi Shaw received a grant of stock options, giving the right to buy 19,676 shares of Common Stock at an exercise price of $29.55 per share. The options vest in full on the earlier of one year from grant or immediately before the next annual stockholders' meeting, contingent on continued board service, and expire on June 3, 2036. After this grant, 19,676 derivative securities are reported as held directly.
Beam Therapeutics Inc. director Kathleen E. Walsh received a grant of stock options covering 19,676 shares of Common Stock. The options have an exercise price of $29.55 per share and expire on June 3, 2036.
According to the footnote, the option vests in full on the earlier of the first anniversary of the grant date or immediately before next year's annual stockholder meeting, as long as Walsh continues serving on the board through the vesting date. After this grant, she holds options for 19,676 shares directly.
Beam Therapeutics Inc. director John Maraganore received a grant of stock options covering 19,676 shares of common stock. The options have an exercise price of $29.55 per share and expire on June 3, 2036.
According to the award terms, the option vests in full on the earlier of the first anniversary of the grant date or immediately prior to next year’s annual meeting of stockholders, as long as he continues serving on the board. Following this grant, he holds 19,676 stock options directly and the filing reports no open‑market purchases or sales.
Beam Therapeutics Inc. director Mark Fishman received a grant of stock options covering 19,676 shares of common stock. The options have an exercise price of $29.55 per share and were awarded as compensation, not purchased in the open market.
The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholder meeting, as long as Fishman continues serving on the board through that date. The options expire on June 3, 2036, giving him long-term potential ownership if exercised.
Beam Therapeutics Inc. director Guindo Chirfi received a stock option grant as equity compensation. The award covers 19,676 shares of Beam common stock at an exercise price of $29.55 per share, expiring on June 3, 2036. The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual meeting of stockholders, as long as Chirfi continues serving on the board through the vesting date. This is a non-cash, routine director compensation grant and not an open-market share purchase or sale.
Beam Therapeutics Inc. director Graham K. Cooper reported receiving a grant of stock options to acquire 19,676 shares of common stock. The options have an exercise price of $29.55 per share and expire on June 3, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or immediately before next year’s annual stockholder meeting, provided he continues serving on the board through the vesting date. Following this grant, he holds 19,676 derivative securities directly.
Beam Therapeutics Inc. CEO John M. Evans reported an automatic sale of 30,078 shares of common stock on April 1, 2026 at $24.58 per share. According to the disclosure, these shares were sold in a non-discretionary transaction solely to cover tax withholding obligations tied to previously granted restricted stock units under the company’s 2019 Equity Incentive Plan, pursuant to a Rule 10b5-1 trading plan adopted in May 2023. Following this transaction, Evans directly holds 1,047,205 shares and indirectly holds 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust, which total includes 616 shares acquired under the company’s amended and restated 2019 Employee Stock Purchase Plan on March 31, 2026.
Beam Therapeutics Inc. Chief Medical Officer Amy Simon reported an open-market sale of 6,700 shares of common stock at $24.58 per share. According to the filing, these shares were automatically sold to cover tax withholding obligations tied to vesting of restricted stock units under Beam’s 2019 Equity Incentive Plan and were executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Simon directly holds 102,735 Beam shares, and the total includes shares acquired through the company’s Employee Stock Purchase Plan.
Beam Therapeutics SVP Finance Bethany J. Cavanagh reported an automatic sale of common stock mainly to cover taxes on vesting equity awards. On April 1, 2026, 3,242 shares were sold in an open-market transaction at $24.58 per share. These shares were sold to satisfy tax withholding obligations tied to restricted stock units granted under the company’s 2019 Equity Incentive Plan that vested on multiple March 31 dates from 2022 through 2025. Following the sale, Cavanagh directly holds 51,171 Beam Therapeutics shares. The filing notes the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 9, 2024, indicating the timing was set in advance rather than chosen opportunistically.
Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported an automatic sale of 5,956 shares of common stock on April 1, 2026 at $24.58 per share. After this transaction, she directly holds 109,711 shares of Beam Therapeutics common stock.
The shares were sold in a non-discretionary transaction solely to cover tax withholding obligations arising from the vesting of restricted stock units granted on March 31 of 2022, 2023, 2024 and 2025 under the company’s 2019 Equity Incentive Plan. The sales were effected under a Rule 10b5-1 trading plan adopted on May 19, 2023, indicating the trades were pre-planned rather than opportunistic market sales.
Beam Therapeutics President Giuseppe Ciaramella reported an automatic sale of 11,810 shares of common stock at $24.58 per share. The shares were sold to cover tax withholding obligations tied to previously granted restricted stock units and executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, he directly holds 218,406 shares of Beam Therapeutics common stock.
Bellon Christine reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. reported that Chief Legal Officer Christine Bellon received a grant of 20,000 restricted stock units (RSUs) of common stock on March 31, 2026. Each RSU equals one share and was granted at no cash cost to her.
The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the grant date, conditioned on her continued service with Beam. After this award, she holds 115,667 shares of Beam common stock directly, reflecting a routine, compensation-related equity grant rather than an open-market purchase.
Cavanagh Bethany J reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics reported that SVP, Finance and Treasurer Bethany J. Cavanagh received a grant of 20,000 restricted stock units under the company’s 2019 Equity Incentive Plan. Each RSU represents one share of common stock and vests in four equal annual installments, subject to continued service. Following this award, she holds 54,813 shares directly.
Simon Amy reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. granted Chief Medical Officer Amy Simon 31,750 restricted stock units (RSUs), each representing the right to receive one share of Beam common stock. The RSUs vest in four substantially equal annual installments on the first four anniversaries of the grant date, conditioned on her continued service. Following this award, she directly holds 109,114 shares of Beam common stock, reflecting a compensation-related equity grant rather than an open-market transaction.
Emany Sravan Kumar reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics reported that its Chief Financial Officer, Sravan Kumar Emany, received a grant of 31,750 shares of common stock in the form of restricted stock units under the company’s 2019 Equity Incentive Plan. These RSUs vest in four substantially equal annual installments, starting on the first anniversary of the grant date, if he continues serving at the company. Following this award, his directly held common stock position is 105,456 shares, reflecting compensation tied to long-term service and company performance.
Ciaramella Giuseppe reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. reported that President Giuseppe Ciaramella received an equity grant of 40,000 restricted stock units (RSUs) of common stock. Each RSU represents the right to receive one Beam share and will vest in four substantially equal annual installments, subject to his continued service. Following this award, he directly holds 230,216 shares of Beam common stock, including the RSUs.
Beam Therapeutics CEO John M. Evans reported multiple equity transactions in Beam Therapeutics Inc. stock. He exercised stock options for 50,000 shares of common stock at an exercise price of $0.67 per share, then sold 50,000 shares in open-market transactions at weighted average prices of $22.3692 and $22.7634 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on May 16, 2025. Evans also received 90,000 restricted stock units under the Beam 2019 Equity Incentive Plan, vesting in four equal annual installments, and now holds 986,667 shares directly and 103,000 shares indirectly through a trust.
Beam Therapeutics President Giuseppe Ciaramella reported insider transactions involving 35,000 shares on Common Stock. He exercised a stock option for 35,000 shares at $17.00 per share, converting a derivative award into directly held Common Stock.
On the same date, he then sold 35,000 shares of Common Stock at a weighted average price of $32.0012 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2025. Following these transactions, he directly owned 190,216 shares of Common Stock and 397,313 shares underlying stock options.
Beam Therapeutics Inc. granted a stock option to senior executive Bethany J. Cavanagh, SVP, Finance and Treasurer. On 01/31/2026, she received a stock option to buy 40,000 shares of Common Stock at an exercise price of $27.62 per share, expiring 01/31/2036.
The option was awarded for no cash consideration and is held directly. It vests in equal monthly installments over the 48 months following the grant date, conditioned on her continued service with Beam Therapeutics Inc. through each vesting date.
Beam Therapeutics Inc. reported an insider equity award for its President, Giuseppe Ciaramella. On January 31, 2026, he received a stock option to buy 80,000 shares of common stock at an exercise price of $27.62 per share.
The option was granted directly to him and is scheduled to vest in equal monthly installments over 48 months following the grant date. Each vesting installment is conditioned on his continued service with Beam Therapeutics through the applicable vesting date.
Beam Therapeutics Inc. reported a stock option grant to its Chief Financial Officer, Emany Sravan Kumar. On 01/31/2026, he received a stock option to buy 63,500 shares of Beam Therapeutics common stock at an exercise price of $27.62 per share, expiring on 01/31/2036.
The option vests in equal monthly installments over the 48 months following the grant date, conditioned on his continued service with Beam Therapeutics through each vesting date. Following this grant, he directly held 63,500 derivative securities related to Beam Therapeutics common stock.
Beam Therapeutics Inc. granted Chief Legal Officer Christine Bellon a stock option covering 40,000 shares of common stock. The option has an exercise price of $27.62 per share and expires on January 31, 2036. It was awarded on January 31, 2026 and is held directly.
The option vests in equal monthly installments over 48 months following the grant date, conditioned on Bellon’s continued service with Beam Therapeutics through each vesting date. After this grant, she beneficially owns 40,000 derivative securities in the form of stock options.
Beam Therapeutics CEO John M. Evans reported several stock and option transactions. On January 29–30, 2026, he exercised stock options with a $0.67 exercise price, acquiring 19,336, 5,664 and 25,000 shares of common stock. On the same dates, he sold blocks of 16,333, 8,667, 22,094 and 2,906 shares at weighted average prices ranging from about $27.87 to $29.92, all under a Rule 10b5‑1 trading plan adopted on May 16, 2025. After these trades, he directly beneficially owned 986,667 common shares and indirectly held 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust. On January 31, 2026, he was also granted a new stock option for 180,000 shares at an exercise price of $27.62, vesting in equal monthly installments over 48 months, subject to continued service.
Beam Therapeutics Inc. reported that its Chief Medical Officer, Simon Amy, received a new stock option grant. On January 31, 2026, Simon Amy was awarded a stock option to buy 88,500 shares of Beam common stock at an exercise price of $27.62 per share, expiring on January 31, 2036. The option was granted at no cost to receive it and will vest in equal monthly installments over 48 months, contingent on continued service with Beam Therapeutics through each vesting date.
Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., sold 6,198 shares of common stock on January 22, 2026 at a weighted average price of $35.0005 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 19, 2025. After this transaction, she directly owns 34,813 shares of Beam Therapeutics common stock.
Beam Therapeutics Chief Legal Officer Christine Bellon sold 1,371 shares of Beam Therapeutics common stock at $34 per share on January 22, 2026, under a Rule 10b5-1 trading plan. After this planned sale, she directly beneficially owned 95,667 shares of the company’s common stock. The trading plan was adopted by the reporting person on September 16, 2025, indicating the sale was executed pursuant to a pre-arranged schedule rather than a discretionary, same-day decision.
Beam Therapeutics Inc. senior vice president of finance and treasurer Bethany J. Cavanagh reported a planned sale of company stock. On January 20, 2026, she sold 3,034 shares of Common Stock of Beam Therapeutics at a price of $30.12 per share, leaving her with 41,011 shares beneficially owned directly after the transaction. The sale was carried out under a Rule 10b5-1 trading plan that she adopted on September 19, 2025, which means the trades were pre-arranged according to preset instructions rather than made at her discretion on the trade date.
Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported sales of company common stock in open-market transactions on January 15, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.
She sold blocks of Beam common stock at weighted-average prices of $33.6219, $34.7182 and $35.3988, with each price reflecting multiple trades within disclosed ranges. Following these sales, Bellon directly beneficially owned 97,038 shares of Beam common stock.
Beam Therapeutics (BEAM): A reporting person disclosed an open‑market sale of 459 shares of common stock on 10/27/2025 at $26.68 per share (transaction code S). Following the transaction, indirect beneficial ownership positions were reported as 1,139,443 shares via F‑Prime Capital Partners Healthcare Fund V LP, 14 shares via FMR Capital, Inc., and 841,231 shares held by persons and entities whose shares are subject to reporting by the undersigned.